Trade Viking Therapeutics, Inc. - VKTX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.31 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 79.42 |
| Open | 78.74 |
| 1-Year Change | 271.24% |
| Day's Range | 75.71 - 79.26 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| May 1, 2024 | 76.20 | -2.13 | -2.72% | 78.33 | 80.10 | 75.48 |
| Apr 30, 2024 | 79.42 | 4.67 | 6.25% | 74.75 | 80.09 | 74.67 |
| Apr 29, 2024 | 75.28 | 1.05 | 1.41% | 74.23 | 76.20 | 73.37 |
| Apr 26, 2024 | 74.14 | 5.51 | 8.03% | 68.63 | 74.50 | 68.08 |
| Apr 25, 2024 | 68.75 | 6.28 | 10.05% | 62.47 | 68.95 | 62.45 |
| Apr 24, 2024 | 64.92 | 0.02 | 0.03% | 64.90 | 67.62 | 64.33 |
| Apr 23, 2024 | 64.82 | 0.63 | 0.98% | 64.19 | 67.41 | 63.42 |
| Apr 22, 2024 | 63.74 | 0.09 | 0.14% | 63.65 | 64.78 | 62.13 |
| Apr 19, 2024 | 63.25 | -0.85 | -1.33% | 64.10 | 65.58 | 61.52 |
| Apr 18, 2024 | 64.55 | -1.13 | -1.72% | 65.68 | 66.03 | 64.39 |
| Apr 17, 2024 | 66.35 | -2.71 | -3.92% | 69.06 | 69.50 | 66.02 |
| Apr 16, 2024 | 67.79 | 1.66 | 2.51% | 66.13 | 68.29 | 65.39 |
| Apr 15, 2024 | 66.81 | -1.90 | -2.77% | 68.71 | 69.68 | 66.10 |
| Apr 12, 2024 | 68.50 | -1.23 | -1.76% | 69.73 | 70.46 | 68.28 |
| Apr 11, 2024 | 70.75 | -0.22 | -0.31% | 70.97 | 71.49 | 70.26 |
| Apr 10, 2024 | 71.50 | 1.35 | 1.92% | 70.15 | 71.62 | 68.18 |
| Apr 9, 2024 | 72.70 | -2.37 | -3.16% | 75.07 | 75.92 | 71.63 |
| Apr 8, 2024 | 75.69 | 0.45 | 0.60% | 75.24 | 76.63 | 73.92 |
| Apr 5, 2024 | 76.26 | 2.79 | 3.80% | 73.47 | 77.57 | 72.28 |
| Apr 4, 2024 | 73.54 | -5.57 | -7.04% | 79.11 | 79.73 | 73.19 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Viking Therapeutics, Inc. Company profile
About Viking Therapeutics Inc
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for metabolic and endocrine disorders. The Company's lead clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß). The Company is conducting VOYAGE study, a phase II b clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). It is also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRß for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is engaged in a phase I b clinical trial of VK0214 in patients with X-ALD. Its other clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator (SARM).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Viking Therapeutics Inc revenues was not reported. Net loss increased 39% to $55M. Higher net loss reflects Other Research and Development. increase of 42% to $43.4M (expense), Interest Income - Net decrease of 78% to $703K (income), Stock-based Compensation in R&D increase of 19% to $1.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.54 to -$0.71.
| Industry: | Bio Therapeutic Drugs |
9920 Pacific Heights Blvd, Suite 350
SAN DIEGO
CALIFORNIA 92121
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com